for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Can Fite Biopharma Ltd

CANF.A

Latest Trade

1.90USD

Change

0.01(+0.53%)

Volume

16,881

Today's Range

1.83

 - 

1.92

52 Week Range

1.08

 - 

2.95

As of on the Tel Aviv Stock Exchange ∙ Minimum 15 minute delay

Pricing

Previous Close
1.89
Open
1.85
Volume
16,881
3M AVG Volume
35.85
Today's High
1.92
Today's Low
1.83
52 Week High
2.95
52 Week Low
1.08
Shares Out (MIL)
463.77
Market Cap (MIL)
96.79
Forward P/E
--
Dividend (Yield %)
--

Latest Developments

More

Can-Fite Biopharma Says As Of September 30, 2020, Co Had Cash And Cash Equivalents Of $10.22 Million

FDA Clears Can-Fite To Commence Phase II COVID-19 Study

Can-Fite Reports Second Quarter 2020 Financial Results & Provides Clinical Update

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Can Fite Biopharma Ltd

Can Fite Biofarma Ltd is an Israel-based biopharmaceutical company. The Company develops new treatments for autoimmune diseases and cancer. The Company’s drugs are CF101 for Psoriasis treatment, RA treatment, for the treatment of Keratoconjunctictivitis Sicca, for the treatment of Glaucoma, among others; and CF102 for the treatment of liver diseases. The Company has a research infrastructure including research laboratories and animal house facilities run by the development team. Can Fite Biofarma Ltd signed distribution contracts with a Kwang Dong Pharmaceutical Co. allowing distribution of CF101 for arthritis in Korea and Seikagaku Corp. for distribution in Japan. The Company operates three subsidiaries, Ultratrend Ltd, EyeFite Ltd and OphathaliX Inc.

Industry

Biotechnology & Drugs

Contact Info

10 Bareket Street, Kiryat Matalon,

P.O. Box 7537

4951778

Israel

+972.3.9241114

http://www.canfite.com/

Executive Leadership

Ilan Cohen

Chairman of the Board

Pnina Fishman

Chief Executive Officer, Director

Motti Farbstein

Chief Financial Officer, Chief Operating Officer

Golan Bitton

Director

Guy Regev

Director

Key Stats

Price To Earnings (TTM)
--
Price To Sales (TTM)
37.78
Price To Book (MRQ)
3.18
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
--
LT Debt To Equity (MRQ)
--
Return on Investment (TTM)
-124.73
Return on Equity (TTM)
-100.14

Latest News

Latest News

BRIEF-Can Fite Biopharma Files For Offering Of Up To 96.7 Mln Ordinary Shares By The Selling Shareholders

* CAN FITE BIOPHARMA LTD FILES FOR OFFERING OF UP TO 96.7 MILLION ORDINARY SHARES BY THE SELLING SHAREHOLDERS - SEC FILING Source text (https://bit.ly/300uNl8) Further company coverage:

BRIEF-Can-Fite Announces Final Data Analysis From Phase Ii Nash Study Highly Significant

* CAN-FITE ANNOUNCES FINAL DATA ANALYSIS FROM PHASE II NASH STUDY: HIGHLY SIGNIFICANT AND SUSTAINED REDUCTION IN LIVER FAT VOLUME THROUGHOUT STUDY PERIOD

BRIEF-Can Fite Files Prospectus Supplement To Offer 117.1 Million Ordinary Shares Represented By 3.9 Million ADSs

* CAN FITE BIOPHARMA LTD FILES PROSPECTUS SUPPLEMENT TO OFFER 117.1 MILLION ORDINARY SHARES REPRESENTED BY 3.9 MILLION ADSS - SEC FILING

BRIEF-Can-Fite Announces $8 Million Registered Direct Offering

* CAN FITE BIOPHARMA -PURCHASE & SALE OF 3.9 MILLION OF CO'S ADSS, AT PURCHASE PRICE OF $2.05/ADS, IN A REGISTERED DIRECT OFFERING Source text for Eikon: Further company coverage:

BRIEF-Can-Fite To Advance Piclidenoson Into Phase II Covid-19 Trial In The U.S.

* FOLLOWING PRE-IND GUIDANCE FROM FDA CAN-FITE TO ADVANCE PICLIDENOSON INTO PHASE II COVID-19 TRIAL IN THE U.S.

BRIEF-Can-Fite Concludes Meeting With EMA Regarding Phase III Trial For Namodenoson

* CAN-FITE CONCLUDES SUCCESSFUL MEETING WITH EUROPEAN MEDICINES AGENCY (EMA) REGARDING PHASE III TRIAL AND REGISTRATION PLAN FOR NAMODENOSON IN THE TREATMENT OF LIVER CANCER

BRIEF-Can-Fite Reports Qtrly Loss Per Share $0.03

* CAN-FITE REPORTS FIRST QUARTER 2020 FINANCIAL RESULTS & PROVIDES CLINICAL UPDATE

BRIEF-Can-Fite Receives Notice Of Allowance For Namodenoson Patent In The Treatment Of Nash & Nafld From U.S. Patent And Trademark Office

* CAN-FITE RECEIVES NOTICE OF ALLOWANCE FOR NAMODENOSON PATENT IN THE TREATMENT OF NASH & NAFLD FROM U.S. PATENT AND TRADEMARK OFFICE Source text for Eikon: Further company coverage: (Reuters.Briefs@thomsonreuters.com)

BRIEF-Can-Fite Reports Additional Findings From Successful Phase II Nash Study

* CAN-FITE REPORTS ADDITIONAL FINDINGS FROM SUCCESSFUL PHASE II NASH STUDY: 25 MG DOSE OF NAMODENOSON SIGNIFICANTLY REDUCED LIVER FAT AND FIBROSIS

BRIEF-Can-Fite Announces Pre-Ind Submission To FDA For Piclidenoson

* CAN-FITE ANNOUNCES PRE-IND SUBMISSION TO U.S. FDA FOR PICLIDENOSON IN THE TREATMENT OF COVID-19 INFECTED PATIENTS WITH MODERATE-TO-SEVERE SYMPTOMS

BRIEF-Can Fite Received Approval For COVID-19 Clinical Trial In Israel, Patient Enrollment And Dosing To Commence Immediately

* CAN FITE RECEIVED APPROVAL FOR COVID-19 CLINICAL TRIAL IN ISRAEL, PATIENT ENROLLMENT AND DOSING TO COMMENCE IMMEDIATELY Source text for Eikon: Further company coverage:

BRIEF-Can-Fite Reports Positive Results From Phase 2 Nash Study

* CAN-FITE REPORTS POSITIVE TOP LINE RESULTS FROM ITS PHASE II NASH STUDY WITH NAMODENOSON

BRIEF-Can-Fite Implements Interim Analysis For Its Phase III Psoriasis Trial

* CAN-FITE IMPLEMENTS INTERIM ANALYSIS FOR ITS PHASE III PSORIASIS TRIAL WITH DATA EXPECTED Q4 2020

BRIEF-Can-Fite Reports 2019 Financial Results & Provides Clinical Development Update

* CAN-FITE REPORTS 2019 FINANCIAL RESULTS & PROVIDES CLINICAL DEVELOPMENT UPDATE

BRIEF-Can Fite Biopharma Says Piclidenoson Submitted For Compassionate Use Treatment For Coronavirus Patients In Israel

* CAN FITE BIOPHARMA LTD - PICLIDENOSON SUBMITTED FOR COMPASSIONATE USE TREATMENT FOR CORONAVIRUS PATIENTS IN ISRAEL Source text for Eikon: Further company coverage:

BRIEF-Can Fite Biopharma Ltd - Looks To Partner On Co-Development Of Piclidenoson For Coronavirus Treatment

* CAN FITE BIOPHARMA LTD - LOOKS TO PARTNER ON CO-DEVELOPMENT OF PICLIDENOSON FOR CORONAVIRUS TREATMENT Source text for Eikon: Further company coverage:

BRIEF-Can Fite Biopharma Ltd - Enrolled 7 Patients For Compassionate Use Program For Namodenoson In Treatment Of Hepatocellular Cancer

* CAN FITE BIOPHARMA LTD - ENROLLED 7 PATIENTS FOR COMPASSIONATE USE PROGRAM FOR NAMODENOSON IN TREATMENT OF HEPATOCELLULAR CANCER

BRIEF-Can-Fite To Explore The Anti-Coronavirus Effects Of Piclidenoson In Collaboration With Lewis Katz School Of Medicine At Temple University

* CAN-FITE TO EXPLORE THE ANTI-CORONAVIRUS EFFECTS OF PICLIDENOSON IN COLLABORATION WITH LEWIS KATZ SCHOOL OF MEDICINE AT TEMPLE UNIVERSITY Source text for Eikon: Further company coverage:

BRIEF-Can-Fite Updates On Clinical Milestone For Its Phase III Rheumatoid Arthritis Study With Piclidenoson; Drugs Combating Rheumatoid Arthritis Are Currently Introduced For The Treatment Of The Coronavirus

* CAN-FITE UPDATES ON CLINICAL MILESTONE FOR ITS PHASE III RHEUMATOID ARTHRITIS STUDY WITH PICLIDENOSON; DRUGS COMBATING RHEUMATOID ARTHRITIS ARE CURRENTLY INTRODUCED FOR THE TREATMENT OF THE CORONAVIRUS

BRIEF-Can Fite Biopharma Says Filing Drug Safety Update Report Showing Positive Safety Results From Phase II & Phase III Studies Of Namodenoson & Piclidenoson

* CAN FITE BIOPHARMA - FILING DRUG SAFETY UPDATE REPORT SHOWING POSITIVE SAFETY RESULTS FROM PHASE II & PHASE III STUDIES OF NAMODENOSON & PICLIDENOSON Source text for Eikon: Further company coverage:

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up